Aligning the Evidence with the Patient to Individualize Treatment Considerations Along the CML Care Continuum

/ Print /
| ShareMore
/ Text Size +
12/10/21 3:00 pm EDT
Virtual Webinar

The unprecedented transformation of the chronic myeloid leukemia (CML) treatment landscape over the last 20 years has led to the life expectancy of patients with CML approaching that of the general population. However, numerous clinical challenges remain for clinicians caring for patients with CML, including recognition of milestones, treating patients with suboptimal response, sequencing therapies, assessing and treating patients with resistance mutations, considerations for therapy cessation, and managing treatment-related adverse events. Because most patients remain on therapy long-term, clinicians must continually optimize side-effect management and treatment adherence for the care of these patients.

Learning Objectives

The learning objectives of this program are:

  • Assess recent clinical trial evidence concerning the efficacy and safety of evolving TKI approaches and their application to the care of patients with CML in multiple lines of therapy
  • Apply shared decision-making and monitoring strategies that can inform therapeutic switching evaluations along the CML disease continuum, including frontline and relapsed CML settings
  • Determine methods to personalize decisions for patients with CML who may require switching based on risk for relapse, performance status, and treatment-related toxicities
  • Align patient goals with trial evidence and clinical guidelines to facilitate shared decisions along the CML care continuum

Target Audience

This educational program is directed toward academic and community hematologists, medical oncologists, and other health care professionals interested in the latest advances in the treatment of patients with CML. Pathologists, histologists, fellows, researchers, nurses, nurse practitioners, physician assistants, pharmacists, and other health care professionals interested in the treatment of patients with CML are also invited to attend.


December 10, 2021

3:00 PM – 5:30 PM ET